基因组背景对接受基因型匹配靶向治疗的实体瘤患者结局的影响:一项全面综述
该综述在PubMed、Cochrane系统综述数据库和PROSPERO进行范围检索,纳入报告两个分子亚队列数据的固定效应Meta分析。结果显示 concomitant驱动突变、较高TMB、较大拷贝数负荷和APOBEC特征可显著降低从不吸烟肺癌和乳腺癌的靶向治疗获益。
要点
- concomitant驱动突变、较高TMB、较大拷贝数负荷和APOBEC特征显著降低从不吸烟肺癌和乳腺癌的靶向治疗获益。
- 从不吸烟肺癌伴p53共突变者结局显著更差,HER2阳性乳腺癌(曲妥珠单抗)和头颈癌(PI3K抑制)亦见类似效应。
- PI3K共改变对靶向EGFR突变和ALK融合影响较小,但显著降低靶向HER2和MET扩增的效果;SMARCA4共突变预示奥希替尼和索托拉西布治疗结局差。
核心结论
- 据作者所知,这是迄今关于基因组背景对靶向治疗结局影响的最全面综述,为情境化精准医学提供资源。
研究设计与样本
- 全面叙述性综述:在PubMed、Cochrane系统综述数据库和PROSPERO进行范围检索;Meta分析结局包括无进展生存和总生存,数据从Kaplan-Meier提取并计算风险比。
- 报告两个分子亚队列(如共突变与无共突变)数据的研究纳入固定效应Meta分析,其他研究用于描述性目的。
主要发现
- 从不吸烟肺癌(终生吸烟少于100支)中, concomitant驱动突变、较高肿瘤突变负荷(TMB)、较大拷贝数负荷和APOBEC特征显著降低靶向治疗获益;在低TMB乳腺癌中亦显著降低获益。
- 从不吸烟肺癌伴p53共突变者结局显著更差,该效应亦见于人表皮生长因子受体2阳性(HER2+)乳腺癌患者(曲妥珠单抗)和头颈癌患者(磷脂酰肌醇3-激酶(PI3K)抑制)。
- PI3K共改变在靶向表皮生长因子受体突变和间变性淋巴瘤激酶融合时影响较小,但显著降低靶向HER2和MET扩增的效果。
- SMARCA4共突变预示接受奥希替尼和索托拉西布治疗的患者结局差。
- 在BRAF突变黑色素瘤中,无基因组特征区分卓越缓解者与原发性进展者,但有明确的转录组特征可将这两种结局二分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A critical need in the field of genotype-matched targeted therapy in cancer is to identify patients unlikely to respond to precision medicines. This will manage expectations of individualised therapies and avoid clinical progression to a point where institution of alternative treatments might not be possible. We examined the evidence base of the impact of genomic context on which targeted alterations are inscribed to identify baseline biomarkers distinguishing those obtaining the expected response from those with less benefit from targeted therapies. METHODS: A comprehensive narrative review was conducted: scoping searches were undertaken in PubMed, Cochrane Database of Systematic Reviews, and PROSPERO. Outcomes included in meta-analysis were progression-free and overall survival. Data were extracted from Kaplan-Meier and used to calculate hazard ratios. Studies presenting data on two molecular subcohorts (e.g. co-mutation versus no co-mutation) were included in fixed meta-analysis. Other studies were used for descriptive purposes. RESULTS: The presence of concomitant driver mutations, higher tumour mutational burden (TMB), greater copy number burden, and APOBEC signatures significantly reduces benefits of targeted therapy in lung cancers in never smokers (LCINS - less than 100 cigarettes per lifetime) and breast cancer, cancers with low TMB. LCINS have significantly poorer outcomes if their cancers harbour p53 co-mutations, an effect also seen in human epidermal growth factor receptor 2-positive (HER2+) breast cancer patients (trastuzumab) and head and neck cancer patients [phosphoinositide 3-kinase (PI3K) inhibition]. PI3K co-alterations have less impact when targeting epidermal growth factor receptor mutations and anaplastic lymphoma kinase fusions, but significantly reduce the impact of targeting HER2 and MET amplifications. SMARCA4 co-mutations predict for poor outcome in patients treated with osimertinib and sotorasib. In BRAF-mutant melanoma, whilst there are no genomic features distinguishing exceptional responders from primary progressors, there are clear transcriptomic features dichotomising these outcomes. CONCLUSION: To our knowledge, this is the most comprehensive review to date of the impact of genomic context on outcomes with targeted therapy. It represents a valuable resource informing progress towards contextualised precision medicine.
引用
- Fulton-Ward T, Middleton G. The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review. Ann Oncol. 2023. PMID: 37875224. doi:10.1016/j.annonc.2023.10.124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。